United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY

UNITED THERAPEUTICS Corp

2022-Q1 EPS reported $5.03 revenue$461,900,000

Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.
Net income $239.9M (diluted EPS $5.03) vs $28.3M ($0.61) in Q1 2021; earnings surge primarily due to strong revenue and lower R&D spend.
Tyvaso DPI NDA under FDA review with decision expected in May 2022; company awaits outcome of citizen petition and inspection issues.
Phase 3 TETON 1 & 2 studies for IPF, PERFECT for PH-COPD, and ADVANCE trials for ralinepag are enrolling or commencing.
Orenitram revenue grew 14% YoY to $82.8M on volume and price; Remodulin flat at $131.7M with U.S. decline offset by international orders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.